| Brad C Anderson, DPM | |
|
2400 32nd Ave S, Fargo, ND 58103-5800 | |
| (701) 234-8720 | |
| (701) 234-8779 |
| Full Name | Brad C Anderson |
|---|---|
| Gender | Male |
| Speciality | Podiatry |
| Experience | 27 Years |
| Location | 2400 32nd Ave S, Fargo, North Dakota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1649298381 | NPI | - | NPPES |
| 11706 | Medicaid | ND |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213E00000X | Podiatrist | 673 (Minnesota) | Secondary |
| 213E00000X | Podiatrist | 46 (North Dakota) | Secondary |
| 213ES0103X | Podiatrist - Foot & Ankle Surgery | 46 (North Dakota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Sanford Medical Center Fargo | Fargo, ND | Hospital |
| Chi Mercy Health | Valley city, ND | Hospital |
| Jamestown Regional Medical Center | Jamestown, ND | Hospital |
| Perham Health | Perham, MN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Sanford Clinic North | 4284546151 | 84 |
| Sanford Medical Center Fargo | 8426967803 | 1094 |
News Archive
Stem Cell Therapy International, Inc. announced that its soon to be subsidiary, Histostem Ltd. of South Korea ("Histostem"), has been awarded U.S. Patent Number 7,582,477 B2, entitled "Method of Isolating and Culturing Mesenchymal Stem Cell Derived from Cryopreserved Umbilical Cord Blood." This patented method is utilized across the company for research, clinical and cosmetic applications.
Researchers in the Department of Chemistry at Wake Forest University in collaboration with colleagues at the Wake Forest University Health Sciences Comprehensive Cancer Center have developed a new class of platinum-based anti-tumor drugs that animal studies have shown to be 10 times more effective than current treatments in destroying certain types of lung cancer cells.
Please be advised that Gallup and Healthways, Inc. today released the Gallup-Healthways Monthly U.S. Well-Being Report for October 2010.
Affymax, Inc. and Takeda Pharmaceutical Company Limited, today announced results of additional analyses from two Phase 3 studies of the investigational agent, peginesatide in chronic renal failure patients on dialysis with anemia.
› Verified 9 days ago
| Provider Name | Sanford Clinic North |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1942241351 PECOS PAC ID: 4284546151 Enrollment ID: O20031112000221 |
News Archive
Stem Cell Therapy International, Inc. announced that its soon to be subsidiary, Histostem Ltd. of South Korea ("Histostem"), has been awarded U.S. Patent Number 7,582,477 B2, entitled "Method of Isolating and Culturing Mesenchymal Stem Cell Derived from Cryopreserved Umbilical Cord Blood." This patented method is utilized across the company for research, clinical and cosmetic applications.
Researchers in the Department of Chemistry at Wake Forest University in collaboration with colleagues at the Wake Forest University Health Sciences Comprehensive Cancer Center have developed a new class of platinum-based anti-tumor drugs that animal studies have shown to be 10 times more effective than current treatments in destroying certain types of lung cancer cells.
Please be advised that Gallup and Healthways, Inc. today released the Gallup-Healthways Monthly U.S. Well-Being Report for October 2010.
Affymax, Inc. and Takeda Pharmaceutical Company Limited, today announced results of additional analyses from two Phase 3 studies of the investigational agent, peginesatide in chronic renal failure patients on dialysis with anemia.
› Verified 9 days ago
| Provider Name | Sanford Medical Center Fargo |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1184917924 PECOS PAC ID: 8426967803 Enrollment ID: O20110331000495 |
News Archive
Stem Cell Therapy International, Inc. announced that its soon to be subsidiary, Histostem Ltd. of South Korea ("Histostem"), has been awarded U.S. Patent Number 7,582,477 B2, entitled "Method of Isolating and Culturing Mesenchymal Stem Cell Derived from Cryopreserved Umbilical Cord Blood." This patented method is utilized across the company for research, clinical and cosmetic applications.
Researchers in the Department of Chemistry at Wake Forest University in collaboration with colleagues at the Wake Forest University Health Sciences Comprehensive Cancer Center have developed a new class of platinum-based anti-tumor drugs that animal studies have shown to be 10 times more effective than current treatments in destroying certain types of lung cancer cells.
Please be advised that Gallup and Healthways, Inc. today released the Gallup-Healthways Monthly U.S. Well-Being Report for October 2010.
Affymax, Inc. and Takeda Pharmaceutical Company Limited, today announced results of additional analyses from two Phase 3 studies of the investigational agent, peginesatide in chronic renal failure patients on dialysis with anemia.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Brad C Anderson, DPM Po Box 2010, Fargo, ND 58122-0605 Ph: () - | Brad C Anderson, DPM 2400 32nd Ave S, Fargo, ND 58103-5800 Ph: (701) 234-8720 |
News Archive
Stem Cell Therapy International, Inc. announced that its soon to be subsidiary, Histostem Ltd. of South Korea ("Histostem"), has been awarded U.S. Patent Number 7,582,477 B2, entitled "Method of Isolating and Culturing Mesenchymal Stem Cell Derived from Cryopreserved Umbilical Cord Blood." This patented method is utilized across the company for research, clinical and cosmetic applications.
Researchers in the Department of Chemistry at Wake Forest University in collaboration with colleagues at the Wake Forest University Health Sciences Comprehensive Cancer Center have developed a new class of platinum-based anti-tumor drugs that animal studies have shown to be 10 times more effective than current treatments in destroying certain types of lung cancer cells.
Please be advised that Gallup and Healthways, Inc. today released the Gallup-Healthways Monthly U.S. Well-Being Report for October 2010.
Affymax, Inc. and Takeda Pharmaceutical Company Limited, today announced results of additional analyses from two Phase 3 studies of the investigational agent, peginesatide in chronic renal failure patients on dialysis with anemia.
› Verified 9 days ago
Robert Renschler, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 1702 South University Drive, Eh South University Clinic, Fargo, ND 58103 Phone: 701-364-3300 Fax: 701-364-8906 | |
Dr. Ryan Jameson, DPM Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 1720 University Dr S Fl 4b, Fargo, ND 58103 Phone: 701-417-4335 | |
A Foot Doctor, Pllc Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 2631 12th Ave S, Fargo, ND 58103 Phone: 701-232-0900 | |
Dr. Mark Domaas, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 4450 31st Ave S, Ste 102, Fargo, ND 58104 Phone: 701-566-8721 Fax: 701-205-4593 | |
Timothy P Uglem, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 2400 32nd Ave S, Fargo, ND 58103 Phone: 701-234-8770 Fax: 701-234-8779 | |
John Paul Naughton, D.P.M. Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 2400 32nd Ave S, Fargo, ND 58103 Phone: 701-234-2000 Fax: 701-234-8803 |